The FDA plans to update the label of montelukast sodium (Singulair, Merck) zafirlukast (Accolate, AstraZeneca), and zileuton (Zyflo, Cornerstone) with a precaution concerning neuropsychiatric events such as agitation, depression, insomnia, and suicidal thinking.

Read the rest of this entry »